ArticleDiscover oncology2025
The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Validation of a UPLC-MS/MS Method for Quantifying Intracellular Olaparib Levels in Resistant Ovarian Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis meta-analysis aims to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with recurrent ovarian cancer, with particular emphasis on those with platinum-resistant disease.
methodA comprehensive search of PubMed, EMBASE, and the Cochrane Library was conducted through August 31, 2025. Data on progression-free survival (PFS), overall response rate (ORR), overall survival (OS), duration of response (DOR), cancer antigen 125 response, and treatment-related adverse events (TRAEs) were extracted and analyzed using meta-analysis to assess the efficacy and safety of MIRV.
resultTwelve studies involving a total of 1112 patients with recurrent ovarian cancer were included in this meta-analysis. The PFS with MIRV was 6.28 months (95% confidence interval CI 5.70-6.87), and the ORR was 0.37 (95% CI 0.34-0.40). Among platinum-resistant patients treated with a combination of MIRV and bevacizumab, the PFS was 7.66 months (95% CI 6.45-8.87), while the ORR reached 0.42 (95% CI, 0.34-0.50). In addition, MIRV achieved an OS of 16.00 months (95% CI 12.36-19.63) and a DOR of 7.69 months (95% CI 6.80-8.58). The overall incidence of TRAEs was 93% (95% CI 92-95), with grade ≥ 3 adverse events occurring in 34% of patients (95% CI 31-37). The most common TRAEs were blurred vision (incidence 0.45; 95% CI, 0.42-0.48), nausea (0.39; 95% CI 0.37-0.42), and diarrhea (0.37; 95% CI 0.34-0.39).
conclusionMIRV demonstrates significant efficacy and an acceptable safety profile in the treatment of recurrent ovarian cancer. Its use in platinum-resistant ovarian cancer with high FRα expression represents a particularly promising Therapeutic approach. Furthermore, the combination of MIRV and bevacizumab shows substantial potential for improving outcomes in patients with platinum-resistant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.